statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Gagnants
Le titre IN8bio (NASDAQ:INAB) a augment mardi de 31,19% 1,43 dollars lors de la session after-market.
L'action ImmuCell (NASDAQ:ICCC) a grimp de 11,11% 5,80 dollars.
L'action aTyr...

12 titres de soins de sant  en mouvement lors de la session apr s-cl ture le 09/04/2024

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

We're Keeping An Eye On IN8bio's (NASDAQ:INAB) Cash Burn Rate

Laidlaw initiated coverage on shares of IN8bio (NASDAQ:INAB  Free Report) in a report published on Monday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $7.50 price...

IN8bio (NASDAQ:INAB) Receives New Coverage from Analysts at Laidlaw

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

IN8bio initiated with bullish view at Laidlaw, here's why

Reported the First-Ever Durable Persistence of an Allogeneic Cellular Therapy from a Phase 1 Study of INB-100 in Leukemia where 100% of Evaluable Patients (n=10) Treated Remained in Remission...

IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

Compugen (NASDAQ:CGEN  Get Free Report) and IN8bio (NASDAQ:INAB  Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two...

IN8bio (NASDAQ:INAB) vs. Compugen (NASDAQ:CGEN) Head-To-Head Contrast

New preclinical data demonstrating proof-of-concept for the non-signaling gamma-delta T cell CAR (nsCAR) platform candidate targeting CD-33 and CD-123 will be presented.The platform has demonstrated...

IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024

IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and Co-founder, will present...

IN8bio to Present at Upcoming Investor Conferences

Peer-reviewed publication discusses current strategy and future direction of new treatment for glioblastoma using novel gamma-delta T cell based adoptive cellular therapyNEW YORK, Feb. 14, 2024...

IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology

Shares of IN8bio, Inc. (NASDAQ:INAB  Get Free Report) fell 7.7% during trading on Thursday . The company traded as low as $1.19 and last traded at $1.20. 618,406 shares changed hands during...

IN8bio (NASDAQ:INAB) Stock Price Down 7.7%

IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.

Volume	1,363.00
52-Wk High	$3.48
52-Wk Low	$0.65

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.17	--	--	N/A
Q4'23	-$0.15	-$0.22	-43.48%	MISSED
Q3'23	-$0.25	-$0.23	6.12%	BEAT
Q2'23	-$0.27	-$0.27	--	EXPECTED
Q1'23	-$0.32	-$0.30	6.25%	BEAT

INAB IN8bio Inc

About

Feed

News

Earnings

Fundamentals